Skip to content

DARPA – Alert Warefighter Enablement (AWARE) Phase 0 – DARPA-PS-24-17

Home / Funding Opportunity / DARPA – Alert Warefighter Enablement (AWARE) Phase 0 – DARPA-PS-24-17

DARPA – Alert Warefighter Enablement (AWARE) Phase 0 – DARPA-PS-24-17

twitterlinkedin

DARPA is seeking innovative approaches to address challenges with maintaining warfighter alertness following sleep deprivation.  AWARE aims to develop a combination drug and device to non-invasively increase alertness following sleep loss in humans, without negative side effects such  as anxiety, irritability or euphoria, and with reduced addictive potential.

Specifically, AWARE aims include the development of

  1.  candidate photoswitchable dextroamphetamine (“PhotoDex”) molecules that are biologically inert in dark conditions but are reversibly activated in the presence of near infrared (NIR) light (750- 900 nm);
  2. wearable device elements that emit NIR light at 850 nm to a depth of 1.5 cm, adaptable to any wavelength between 750 and 900 nm to accommodate the final optimal PhotoDex wavelength.

This Phase 0 will run for 15 months.

Abstracts are required and are due 12 July 2024.  Selected abstract proposers will be invited to provide and oral proposal, 1 – 2 August 2024.

 

Read more

Document

Funding Opportunity – AWARE: DARPA-PS-24-17

 

 

You may be also interested in ...